Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of CKPT is 4.2 and suggests 2% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
Buy
Sell